Entera Bio Ltd. (NASDAQ:ENTX – Get Rating) was the target of a significant increase in short interest during the month of December. As of December 30th, there was short interest totalling 61,100 shares, an increase of 8.5% from the December 15th total of 56,300 shares. Based on an average daily trading volume, of 124,800 shares, the short-interest ratio is currently 0.5 days.
Entera Bio Trading Up 3.3 %
Shares of NASDAQ:ENTX traded up $0.03 on Tuesday, hitting $0.95. The company had a trading volume of 18,105 shares, compared to its average volume of 90,480. Entera Bio has a 1-year low of $0.47 and a 1-year high of $3.00. The stock has a market cap of $27.36 million, a price-to-earnings ratio of -6.82 and a beta of 1.75. The stock has a 50 day moving average price of $0.73 and a 200 day moving average price of $1.08.
Get
Entera Bio alerts:
Entera Bio (NASDAQ:ENTX – Get Rating) last released its quarterly earnings data on Thursday, November 10th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.05. Entera Bio had a negative net margin of 1,796.49% and a negative return on equity of 27.72%. The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.07 million. Sell-side analysts anticipate that Entera Bio will post -0.47 earnings per share for the current fiscal year.
Insider Buying and Selling
In other news, CEO Miranda Jayne Toledano bought 50,000 shares of the stock in a transaction that occurred on Friday, November 11th. The shares were acquired at an average cost of $0.53 per share, for a total transaction of $26,500.00. Following the completion of the acquisition, the chief executive officer now owns 56,800 shares in the company, valued at $30,104. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through
this link. 5.15% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Entera Bio
A hedge fund recently bought a new stake in Entera Bio stock. PNC Financial Services Group Inc. acquired a new position in shares of Entera Bio Ltd. (NASDAQ:ENTX – Get Rating) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,000 shares of the company's stock, valued at approximately $29,000. 20.12% of the stock is currently owned by hedge funds and other institutional investors.
Entera Bio Company Profile
(Get Rating)
Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. It s pipeline include PTH, GLP-E, and hGh, The company was founded on September 30, 2009 and is headquartered in Jerusalem, Israel.
Featured Stories
- Get a free copy of the StockNews.com research report on Entera Bio (ENTX)
- Intuit Is About To Make a Move, But Which Way?
- 3 Late January Earnings Plays With Pop Potential
- Low-Priced Stocks Still Paying Dividends
- Why is the Chipotle Stock Price Surging This Week?
- Is the Northrop Grumman Selloff an Opportunity?
Receive News & Ratings for Entera Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entera Bio and related companies with MarketBeat.com's FREE daily email newsletter.
